Expanding our patient cohort is critical to assess the impact of confounders, such as inflammation and other comorbidities, on FGF5 expression and its potential role as a therapeutic target for nasopharyngeal cancer. This evidence concerns the gene FGF5 and nasopharyngeal carcinoma.